Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

[1]  B. van Benthem,et al.  Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18 , 2019, The Journal of infectious diseases.

[2]  M. Sekine,et al.  Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection , 2018, The Journal of infectious diseases.

[3]  M. Poljak,et al.  Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort , 2018, The Journal of infectious diseases.

[4]  M. Arbyn,et al.  Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials , 2018, Expert review of vaccines.

[5]  J. Dillner,et al.  Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development , 2018, Vaccine.

[6]  H. D. de Melker,et al.  High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women , 2018, The Journal of infectious diseases.

[7]  H. Cubie,et al.  Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. , 2017, The Lancet. Infectious diseases.

[8]  J. Cuzick,et al.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial , 2017, The Lancet.

[9]  D. Harper,et al.  HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.

[10]  M. Postma,et al.  Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis , 2017, Japanese journal of clinical oncology.

[11]  J. Dillner,et al.  Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. , 2016, Vaccine.

[12]  M. Pawlita,et al.  Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study , 2016, The Lancet. Oncology.

[13]  Maria Hortlund,et al.  Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine , 2015, Clinical and Vaccine Immunology.

[14]  C. Wheeler,et al.  Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial , 2015, Clinical and Vaccine Immunology.

[15]  M. Lehtinen,et al.  Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study , 2014, BMC Research Notes.

[16]  M. Lehtinen,et al.  Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study , 2014, BMC Research Notes.

[17]  M. Pawlita,et al.  High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses , 2013, PloS one.

[18]  M. Lehtinen,et al.  Clinical trials of human papillomavirus vaccines and beyond , 2013, Nature Reviews Clinical Oncology.

[19]  M. Jit,et al.  A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls , 2013, PloS one.

[20]  M. Lehtinen,et al.  Sound efficacy of prophylactic HPV vaccination , 2012, Oncoimmunology.

[21]  S. Hibbitts.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial , 2012, Journal of Family Planning and Reproductive Health Care.

[22]  C. Wheeler,et al.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[23]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[24]  D. Lowy,et al.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. , 2009, The Journal of infectious diseases.

[25]  F. Schmidt.  Meta-Analysis , 2008 .

[26]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[27]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[28]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.